The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

Insmed (INSM) announced that the U.S. FDA has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis ...

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

Considering taking supplements to treat bronchiectasis? Below is a list of common natural remedies used to treat or reduce the symptoms of bronchiectasis. Follow the links to read common uses ...

In a report released today, Roy Buchanan from JMP Securities maintained a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a ...